Reply to comment on ‘An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers’ by Fukui et al.
Conflict of interest
YM received research funding and honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Daiichi-Sankyo, Kyowa-Kirin, Taiho, and Esai. MN received research funding and honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, Daiichi-Sankyo, Kyowa-Kirin, Taiho, Esai, Novartis, and Denka. The other authors declare that they have no conflicts of interest.
Comments (0)